key: cord-0430562-ca2sqv1u
authors: Florea, A.; Sy, L. S.; Luo, Y.; Qian, L.; Bruxvoort, K. J.; Ackerson, B. K.; Lee, G. S.; Ku, J. H.; Tubert, J. E.; Tian, Y.; Talarico, C. A.; Tseng, H. F.
title: Durability of mRNA-1273 against COVID-19 in the time of Delta: Interim results from an observational cohort study
date: 2021-12-14
journal: nan
DOI: 10.1101/2021.12.13.21267620
sha: 644711d6b2c7f5ea1c0fcb2d0c683a71e74c972f
doc_id: 430562
cord_uid: ca2sqv1u

Background: We conducted a prospective cohort study at Kaiser Permanente Southern California to study the vaccine effectiveness (VE) of mRNA-1273 over time and during the emergence of the Delta variant. Methods: The cohort for this planned interim analysis consisted of individuals aged [≥]18 years receiving 2 doses of mRNA-1273 through June 2021, matched 1:1 to randomly selected unvaccinated individuals by age, sex, and race/ethnicity, with follow-up through September 2021. Outcomes were SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death. Cox proportional hazards models were used to estimate adjusted hazard ratios (aHR) with 95% confidence intervals (CIs) comparing outcomes in the vaccinated and unvaccinated groups. Adjusted VE (%) was calculated as (1-aHR)x100. HRs and VEs were also estimated for SARS-CoV-2 infection by age, sex, race/ethnicity, and during the Delta period (June-September 2021). VE against SARS-CoV-2 infection and COVID-19 hospitalization was estimated at 0-<2, 2-<4, 4-<6, and 6-<8 months post-vaccination. Results: 927,004 recipients of 2 doses of mRNA-1273 were matched to 927,004 unvaccinated individuals. VE (95% CI) was 82.8% (82.2-83.3%) against SARS-CoV-2 infection, 96.1% (95.5-96.6%) against COVID-19 hospitalization, and 97.2% (94.8-98.4%) against COVID-19 hospital death. VE against SARS-CoV-2 infection was similar by age, sex, and race/ethnicity, and was 86.5% (84.8-88.0%) during the Delta period. VE against SARS-CoV-2 infection decreased from 88.0% at 0-<2 months to 75.5% at 6-<8 months. Conclusions: These interim results provide continued evidence for protection of 2 doses of mRNA-1273 against SARS-CoV-2 infection over 8 months post-vaccination and during the Delta period, and against COVID-19 hospitalization and hospital death.

Since coronavirus disease 2019 (COVID-19) vaccine rollout, multiple observational studies have demonstrated that mRNA-1273 (Moderna Inc, Cambridge, USA) is highly effective against symptomatic COVID-19, with reports of vaccine effectiveness (VE) as high as 100% [1] [2] [3] [4] . mRNA-1273 has also been shown to have high VE against COVID-19 hospitalization and death [1, 3] .

However, the emergence of several SARS-CoV-2 variants led to concerns of potentially lower VE of COVID-19 vaccines against variants [5, 6] . The higher transmissibility of the Delta variant led to a surge in infections, hospitalizations, and deaths in the United States (US) since becoming the dominant circulating strain in July 2021 [7, 8] . Even though a majority of cases were in unvaccinated individuals, breakthrough cases among vaccinated individuals have also been reported [9] [10] [11] [12] . We previously evaluated the VE of mRNA-1273 against SARS-CoV-2 variants, and reported an overall VE of 86.7% against Delta infection through July 2021 [13] . Another test-negative observational study in Ontario, Canada, from December 2020 to August 2021, reported a 94% VE against symptomatic infection with Delta after two doses of mRNA-1273 with similar VE against hospitalization and death [14] . Furthermore, several studies conducted in the US post Delta emergence reported high VE of mRNA-1273 against COVID-19 hospitalization ranging from 91.6% to 95.0% [15] [16] [17] .

As the pandemic continues, the durability of protection of COVID-19 vaccines, for which data are limited [18] , and the potential need for boosters have become critical public health questions . We previously reported that waning of VE was most pronounced for the Delta variant, with VE against Delta period in the US. We also evaluated VE and durability against COVID-19 hospitalization.

Kaiser Permanente Southern California (KPSC) is an integrated health care system providing care to a diverse 4.6 million members [20] . KPSC's electronic health record (EHR) is comprehensive, capturing details across several areas such as inpatient, outpatient, emergency, and virtual care; claims also capture any care received outside of the KPSC system. The KPSC Institutional Review Board reviewed and approved the study.

This is the second planned interim analysis (IA) of a 5-year cohort study at KPSC to evaluate the VE of mRNA-1273 in preventing SARS-CoV-2 infection and severe COVID-19 disease. Detailed methods and results of the first IA with follow-up through June 30, 2021 were reported elsewhere [1] . For this analysis, the primary objectives were to evaluate the VE of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection and severe COVID-19 disease. Secondary objectives were to evaluate the VE of 2 doses of mRNA-1273 in preventing SARS-CoV-2 infection by age, sex, and race/ethnicity groups.

We also evaluated the waning of VE over time to assess the durability of mRNA-1273 against SARS-CoV-2 infection and COVID-19 hospitalization. To specifically assess VE against Delta in the absence of waning, we also evaluated VE against Delta infection in individuals newly vaccinated in June 2021 and followed through September 30, 2021. The study protocol is presented in the Supplementary

For the study cohort, eligible individuals were ≥ 18 years old, and were KPSC members for at least 1 year prior to the index date (allowing a 31-day membership gap) and for Baseline characteristics of the vaccinated and unvaccinated groups were described. Continuous variables were compared using two-sample t-test or Wilcoxon rank-sum test, as appropriate, and categorical variables were compared using χ 2 test or Fisher's exact test, as appropriate. Potential confounders were identified based on the literature. To assess the balance of covariates across groups, absolute standardized differences (ASD) were used. Covariates with ASD>0.1, as well as age, sex, race/ethnicity, month of index date were included in the multivariable models. The missing indicator method was used for covariates with missing data [23] .

The number of incident events divided by person-years was used to calculate the incidence rates (IR) per 1,000 person-years of SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death for both vaccinated and unvaccinated groups. Kaplan-Meier curves were used to estimate the cumulative incidence of SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death for both groups; the differences between the curves were tested by log-rank test.

Cox proportional hazards regression models were used to estimate unadjusted and adjusted hazard ratios (HR) with 95% confidence intervals (CIs) comparing SARS-CoV-2 infection, and COVID-19 hospitalization and hospital death in the vaccinated and unvaccinated groups overall. VE (%) was calculated as (1-HR) x 100. HRs and VEs were also estimated comparing SARS-CoV-2 infection in vaccinated and unvaccinated individuals by age, sex, race/ethnicity, and during the Delta period.

To evaluate durability of protection, VE against SARS-CoV-2 infection and COVID-19 hospitalization was estimated every two months post-vaccination (0-<2, 2-<4, 4-<6, and 6-<8 months) using timevarying Cox regression models. VEs by months post-vaccination against SARS-CoV-2 infection and COVID-19 hospitalization were also estimated and stratified by age groups (18-64 years old and ≥ The study cohort consisted of 927,004 recipients of 2 doses of mRNA-1273 vaccine (hereafter, 'vaccinated') and 927,004 matched unvaccinated individuals (Figure 1) . Overall, the median age was 52 years (interquartile range [IQR] 36-65) with 74.3% aged 18-64 years; there were more females than males (54.5%); and 38.6% were Hispanic, 33.6% were non-Hispanic White, 12.8% were Asian, and 7.5% were Black ( Table 1) 

Among vaccinated and unvaccinated groups, the IR of SARS-CoV-2 infection was higher in those 65 years as compared to those ≥ 65 years ( 

Adjusted VE against SARS-CoV-2 infection and COVID-19 hospitalization by months after vaccination both overall and by age groups are presented in Supplementary Table 1 . Adjusted VE against SARS-CoV-2 infection decreased from 88.0% at 0-<2 months to 75.5% at 6-<8 months (Figure 3 ).

Adjusted VE against COVID-19 hospitalization remained stable, from 95.9% in 0-<2 months to 94.5% in 6-<8 months. The durability of protection VE estimates by age groups for both SARS-CoV-2 infection and COVID-19 hospitalization were similar to the overall results.

This interim analysis was conducted among a large cohort to assess the effectiveness and durability of 2 doses of mRNA-1273 under real-world conditions. The study results confirmed the high effectiveness of 2 doses of mRNA-1273, with VE against SARS-CoV-2 infection of 82.8%, VE against COVID-19 hospitalization of 96.1%, and VE against COVID-19 hospital death of 97.2%. Furthermore, VE against COVID-19 hospitalization remained robust and stable over 8 months of follow-up.

Moderate waning was observed for VE against SARS-CoV-2 infection, with a VE of 75.5% at 6-<8 months post-vaccination. The individuals included in the cohort were vaccinated through June 2021 All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The current study is also one of the first to examine the durability of the 2-dose mRNA-1273 vaccine.

While VE against COVID-19 hospitalization was stable during the follow-up, VE against SARS-CoV-2 infection steadily decreased from 88.0% to 75.5% across the 8 months of follow-up. The same VE waning effects were apparent across age categories (18-64 years and ≥ 65 years). These findings are consistent with the findings of our previous study that used a test-negative design [13] . Due to this All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 14, 2021. ; steady decrease in VE, our findings support the current mRNA-1273 booster recommendations of receiving a booster shot at least 6 months after completing the primary series [30] .

One strength of the current study is the matched cohort design which allows for generalizability to the general population eligible for mRNA-1273. Another strength is KPSC's diverse member population.

The study also utilized KPSC's EHR and was able to gather comprehensive data on millions of members; the data included COVID-19 vaccine information, demographics, medical history, and health care utilization. However, residual confounding from unmeasured factors might have still been present. Some health seeking behaviors such as adherence to masking guidelines and occupation are not captured by the EHR; these may contribute to differences in COVID-19 risk and testing behaviors between vaccinated and unvaccinated individuals. Misclassification of SARS-CoV-2 infection from false positive or false negative test results or from inaccurate diagnosis codes from outside claims may have been another limitation. This non-differential misclassification could have underestimated the VE. Lastly, individuals vaccinated during the Delta period were younger as vaccines had recently become available to the general population and may have had fewer COVID-19 risk factors, which could have led to overestimation of VE during the Delta period.

In conclusion, this second interim analysis of an ongoing cohort study found that VE of 2 doses of mRNA-1273 against SARS-CoV-2 infection declined moderately over the course of 8 months, but VE against COVID-19 hospitalization remained robust and stable over the same period. In addition, VE against SARS-CoV-2 infection in newly vaccinated individuals during the Delta period remained high.

Continued long-term follow-up is needed to fully evaluate the real-world effectiveness of mRNA-1273 overall and in different subgroups of the population over time.

All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 14, 2021. ; https://doi.org/10.1101/2021.12.13.21267620 doi: medRxiv preprint e  t  a  l  .  R  e  a  l  -w  o  r  l  d  e  f  f  e  c  t  i  v  e  n  e  s  s  o  f  t  h  e  m  R  N  A  -1  2  7  3  v  a  c  c  i  n  e  a  g  a  i  n  s  t   C  O  V  I  D  -1  9  :  I  n  t  e  r  i  m  r  e  s  u  l  t  s  f  r  o  m  a  p  r  o  s  p  e  c  t  i  v  e  o  b  s  e  r  v  a  t  i  o  n  a  l  c  o  h  o  r  t  s  t  u  d All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 14, 2021. ;

. A  n  d  r  e  w  s  N  ,  T  e  s  s  i  e  r  E  ,  S  t  o  w  e  J  ,  e  t  a  l  .  V  a  c  c  i  n  e  e  f  f  e  c  t  i  v  e  n  e  s  s  a  n  d  d  u  r  a  t  i  o  n  o  f  p  r  o  t  e  c  t  i  o  n  o  f   C  o  m  i  r  n  a  t  y  ,  V  a  x  z  e  v  r  i  a  a  n  d  S  p  i  k  e  v  a  x  a  g  a  i  n  s  t  m  i  l  d  a  n  d  s  e  v  e  r  e  C  O  V  I  D  -1  9  i  n  t  h  e  U  K  .  m  e  d  R  x  i  v   2  0  2  1   :  2  0  2  1  .  0  9  .  1  5  .  2  1  2  6  3  5  8  3  .   2  0  .  K  o  e  b  n  i  c  k  C  ,  L  a  n  g  e  r  -G  o  u  l  d  A  M  ,  G  o  u  l  d  M  K  ,  e  t  a  l  .  S  o  c  i  o  d  e  m  o  g  r  a  p  h  i  c  c  h  a  r  a  c  t  e  r  i  s  t  i  c  s  o  f   m  e  m  b  e  r  s  o  f  a  l  a  r  g  e  ,  i  n  t  e  g  r  a  t  e  d  h  e  a  l  t  h  c  a  r  e  s  y  s  t  e  m  :  c  o  m  p  a  r  i  s  o  n  w  i  t  h  U  S  C  e  n  s  u  s  B  u  r  e  a  u All rights reserved. No reuse allowed without permission. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this this version posted December 14, 2021. ; 

congenital and other immunodeficiencies, asplenia/hyposplenia second doses, days, median (IQR)

Medical center area not shown. The absolute standardized difference of the distribution of the vaccinated and unvaccinated individuals across the 19

categories), sex, race/ethnicity, index date (in months), number of outpatient and virtual visits, preventive care, KPSC physician/employee status

categories, and not adjusted in the age subcohort analysis), sex (not adjusted in the sex subcohort analysis), race/ethnicity (not adjusted in the race/ethnicity subcohort analysis), index date (in months), number of outpatient and virtual visits, preventive care, KPSC physician/employee status, medical center area. b Individuals with index dates in

VE = vaccine effectiveness